LivaNova (NASDAQ:LIVN) Trading Up 7% – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN) shares shot up 7% on Wednesday . The company traded as high as $56.70 and last traded at $56.36. 360,614 shares traded hands during trading, a decline of 46% from the average session volume of 664,206 shares. The stock had previously closed at $52.68.

Analysts Set New Price Targets

A number of research firms recently issued reports on LIVN. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Barclays upped their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the stock a “neutral” rating in a research report on Wednesday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. Finally, Robert W. Baird raised their price target on shares of LivaNova from $61.00 to $63.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

LivaNova Stock Performance

The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The firm has a market cap of $3.09 billion, a PE ratio of -14.56 and a beta of 1.00. The stock’s 50 day moving average price is $53.82 and its 200 day moving average price is $48.63.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.20. The firm had revenue of $357.80 million during the quarter, compared to the consensus estimate of $342.32 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.90 EPS. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, equities analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

Hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in LivaNova by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 179,546 shares of the company’s stock valued at $7,053,000 after purchasing an additional 3,668 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of LivaNova by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company’s stock valued at $1,840,000 after buying an additional 2,901 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of LivaNova by 28.6% during the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock worth $1,897,000 after buying an additional 10,733 shares in the last quarter. CWM LLC increased its stake in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after buying an additional 299 shares during the last quarter. Finally, Foundry Partners LLC bought a new position in LivaNova during the 1st quarter valued at $3,816,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.